Table 2.
Main characteristics of the study populations in the included studies.
| Study | Stage | Follow-up (median/mean months) | Total patients | No. patients in different groups | HR (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Open surgery | Minimal invasive surgery | Laparoscopic surgery | Robotic surgery | OS | DFS | ||||
| Uppal et al. (50) | IA1–IB1 | 30.76 | 815 | 255 | 560 | – | – | 1.01 (0.5–2.2) | 1.88 (1.04–3.25) |
| Pedone Anchora et al. (46) | IA1–IIA1 | 49 | 423 | 217 | – | 206 | – | NA | 0.86 (0.51–1.47) |
| Service NCRaA (49) | IA2, IB, IB1 | 37.2 | 929 | 365 | 564 | – | – | 4.0 (1.5–11.1) | NA |
| Chiva et al. (48) | IB1 | 58 | 245 | 122 | 123 | – | – | 4.25 (1.4–12.9) | 1.94 (1.05–3.58) |
| Paik et al. (30) | IB–IIA | 63.9 | 476 | 357 | – | 119 | – | 0.59 (0.07–4.92) | 2.74 (1.33–5.65) |
| Yuan et al. (31) | IA2–IIA2 | 59 | 198 | 99 | – | 99 | – | 0.94 (0.42–2.09) | 1.52 (0.80–2.89) |
| Cusimano et al. (32) | IB | 72 | 958 | 483 | 475 | – | – | 2.20 (1.15–4.19) | 1.97 (1.10–3.50) |
| Kim et al. (33) | IB1–IIA2 | 114.8 | 593 | 435 | – | 158 | – | 2.22 (1.12–4.41) | 2.88 (1.71–4.86) |
| Doo et al. (34) | IB1 | 25.4 | 105 | 56 | – | – | 49 | 1.49 (0.26–8.65) | 1.63 (0.68–3.90) |
| Lim et al. (35) | IA1–IIA | 27 | 136 | 85 | – | 51 | – | 1.63 (0.48–5.49) | NA |
| Alfonzo et al. (45) | IA1–IB | 44.5 | 864 | 236 | – | – | 628 | 1.00 (0.50–2.01) | 1.08 (0.66–1.78) |
| Ramirez et al. (5) | IA1–IB1 | 30 | 631 | 312 | 319 | 244 | 45 | 6.00 (1.77–20.30) | 3.74 (1.63–8.58) |
| Melamed et al. (29) | IA2,IB1 | 45 | 2,461 | 1,236 | 1,225 | – | 978 | 1.65 (1.22–2.22) | NA |
| Guo et al. (36) | IA1–IIA2 | 39 | 551 | 139 | – | 412 | – | 0.74 (0.37–1.45) | 0.61 (0.29–1.30) |
| Corrado et al. (37) | IB1 | 41.7 | 341 | 101 | – | 152 | 88 | 2.56 (0.52–12.69) | 0.47 (0.07–3.06) |
| Kim et al. (47) | NA | NA | 6,335 | 3,235 | – | 3,100 | – | 0.74 (0.64–0.85) | NA |
| Wallin et al. (38) | IA1–IB1,IIA1 | 62.2 | 304 | 155 | – | – | 149 | NA | 2.13 (1.06–4.26) |
| Shah et al. (39) | IA1–IB2 | NA | 311 | 202 | – | – | 109 | 0.88 (0.23–3.32) | 1.60 (0.75–3.43) |
| Wang et al. (40) | IA2–IIA2 | 68.33 | 406 | 203 | – | 203 | – | 0.77 (0.3–2.02) | 0.98 (0.42–2.26) |
| Sert et al. (41) | IA1–IB2 | 39.6 | 491 | 232 | – | – | 259 | 2.0 (0.43–9.31) | 1.3 (0.62–2.76) |
| Zanagnolo et al. (42) | IA2–IIA | 41.64 | 307 | 104 | – | – | 203 | 1.33 (0.33–5.40) | 0.84 (0.35–2.06) |
| Ditto et al. (13) | IA2,IB1 | 31 | 120 | 60 | – | 60 | – | 0.50 (0.07–3.77) | 0.42 (0.10–2.00) |
| Kong et al. (14) | IB1,IIA | 28 | 88 | 48 | – | 40 | – | NA | 0.28 (0–23.79) |
| Toptas et al. (43) | IA2,IB1 | 42.5 | 68 | 46 | – | 22 | – | 0.53 (0.01–22.5) | 1.18 (0.28–4.96) |
| Nam et al. (12) | IA2–IIA | 92 | 526 | 263 | – | 263 | – | 1.46 (0.62–3.43) | 1.28 (0.62–2.64) |
| Lee et al. (10) | IA2–IIA | 78 | 72 | 48 | – | 24 | – | NA | 0.72 (0.04–12.57) |
| Sobiczewski et al. (44) | IA,IB1,IIA | NA | 80 | 58 | – | 22 | – | NA | 3.14 (0.67–14.73) |
| Malzoni et al. (15) | IA1–IB1 | 52.5 | 127 | 62 | – | 65 | – | NA | 1.15 (0.22–6.09) |
HR, hazard ratio; 95%CI, 95% confidence interval; OS, overall survival; DFS, disease-free survival; NA, not applicable.